Study Of Sunitinib In Combination With Cisplatin And 5-Fluorouracil In Patients With Advanced Gastric Cancer

• Status: Completed
• Trial end date: 2010-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the safe and tolerable dose of sunitinib when given together with cisplatin and 5-fluorouracil in patients with advanced gastric cancer who have not received prior chemotherapy for their advanced cancer.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Cisplatin; Fluorouracil; Sunitinib

Criteria

Inclusion Criteria:

• confirmed diagnosis of stomach cancer

• advanced stomach cancer stage IV

• adequate blood chemistry, blood counts and kidney function

• willing to participate to study requirements and to sign an informed consent document

Exclusion Criteria:

• prior chemotherapy for stomach cancer in its advanced stage

• excessive toxicities related to prior therapies

• pregnant or breastfeeding patients